Pan-cancer Analysis of MC Regulator Genes Reveals Consistent Epigenetic Landscape Changes in Multiple Cancers

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2021 Jul 30

PMID 34325709

Citations 16

Authors

Yuting He

Xiao Yu

Menggang Zhang

Wenzhi Guo

Affiliations

Soon will be listed here.

Abstract

Background: 5-Methylcytosine (mC) is a reversible modification to both DNA and various cellular RNAs. However, its roles in developing human cancers are poorly understood, including the effects of mutant mC regulators and the outcomes of modified nucleobases in RNAs.

Methods: Based on The Cancer Genome Atlas (TCGA) database, we uncovered that mutations and copy number variations (CNVs) of mC regulatory genes were significantly correlated across many cancer types. We then assessed the correlation between the expression of individual mC regulators and the activity of related hallmark pathways of cancers.

Results: After validating mC regulators' expression based on their contributions to cancer development and progression, we observed their upregulation within tumor-specific processes. Notably, our research connected aberrant alterations to mC regulatory genes with poor clinical outcomes among various tumors that may drive cancer pathogenesis and/or survival.

Conclusion: Our results offered strong evidence and clinical implications for the involvement of mC regulators.

Citing Articles

Chen M, Chen Y, Wang K, Deng X, Chen J Clin Transl Med. 2024; 14(6):e1666.

PMID: 38880983 PMC: 11180698. DOI: 10.1002/ctm2.1666.

Modification of m5C regulators in sarcoma can guide different immune infiltrations as well as immunotherapy.

Wu S, Li M, Su R, Shen H, He Y, Zhou Y Front Surg. 2023; 9:948371.

PMID: 36684288 PMC: 9853431. DOI: 10.3389/fsurg.2022.948371.

Comprehensive pan-cancer analysis of N7-methylguanosine regulators: Expression features and potential implications in prognosis and immunotherapy.

Wei W, Liu C, Wang C, Wang M, Jiang W, Zhou Y Front Genet. 2022; 13:1016797.

PMID: 36339001 PMC: 9633684. DOI: 10.3389/fgene.2022.1016797.

The role of RNA modification in hepatocellular carcinoma.

Feng Q, Wang D, Xue T, Lin C, Gao Y, Sun L Front Pharmacol. 2022; 13:984453.

PMID: 36120301 PMC: 9479111. DOI: 10.3389/fphar.2022.984453.

An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer.

Yun D, Yang Z, Zhang S, Yang H, Liu D, Grutzmann R Front Cell Dev Biol. 2022; 10:975684.

PMID: 36060802 PMC: 9437259. DOI: 10.3389/fcell.2022.975684.

References

Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G . Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. Cell Rep. 2018; 25(4):1066-1080.e8. DOI: 10.1016/j.celrep.2018.09.082. View

Costa-Pinheiro P, Montezuma D, Henrique R, Jeronimo C . Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015; 7(6):1003-15. DOI: 10.2217/epi.15.56. View

Krepischi A, Pearson P, Rosenberg C . Germline copy number variations and cancer predisposition. Future Oncol. 2012; 8(4):441-50. DOI: 10.2217/fon.12.34. View

Dong Z, Cui H . The Emerging Roles of RNA Modifications in Glioblastoma. Cancers (Basel). 2020; 12(3). PMC: 7140112. DOI: 10.3390/cancers12030736. View

Mateo J, Lord C, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M . A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019; 30(9):1437-1447. PMC: 6771225. DOI: 10.1093/annonc/mdz192. View

Anastas J, Moon R . WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2012; 13(1):11-26. DOI: 10.1038/nrc3419. View

Tse J, Jenkins L, Chionh F, Mariadason J . Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?. Trends Cancer. 2017; 3(10):698-712. DOI: 10.1016/j.trecan.2017.08.003. View

Gama-Sosa M, Slagel V, Trewyn R, Oxenhandler R, KUO K, GEHRKE C . The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983; 11(19):6883-94. PMC: 326421. DOI: 10.1093/nar/11.19.6883. View

Wu H, Zhang Y . Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 2011; 25(23):2436-52. PMC: 3243055. DOI: 10.1101/gad.179184.111. View

10.

Van Haute L, Lee S, McCann B, Powell C, Bansal D, Vasiliauskaite L . NSUN2 introduces 5-methylcytosines in mammalian mitochondrial tRNAs. Nucleic Acids Res. 2019; 47(16):8720-8733. PMC: 6822013. DOI: 10.1093/nar/gkz559. View

11.

Zhou H, Chen L, Lei Y, Li T, Li H, Cheng X . Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer. Curr Probl Cancer. 2020; 45(2):100660. DOI: 10.1016/j.currproblcancer.2020.100660. View

12.

Du Z, Ma K, Sun X, Li A, Wang H, Zhang L . Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma. World J Surg Oncol. 2015; 13:141. PMC: 4403718. DOI: 10.1186/s12957-015-0557-y. View

13.

Garcia-Vilchez R, Sevilla A, Blanco S . Post-transcriptional regulation by cytosine-5 methylation of RNA. Biochim Biophys Acta Gene Regul Mech. 2018; 1862(3):240-252. DOI: 10.1016/j.bbagrm.2018.12.003. View

14.

Wouters B, Delwel R . Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2015; 127(1):42-52. DOI: 10.1182/blood-2015-07-604512. View

15.

Cui X, Liang Z, Shen L, Zhang Q, Bao S, Geng Y . 5-Methylcytosine RNA Methylation in Arabidopsis Thaliana. Mol Plant. 2017; 10(11):1387-1399. DOI: 10.1016/j.molp.2017.09.013. View

16.

Wang J, Zhu W, Han J, Yang X, Zhou R, Lu H . The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun (Lond). 2021; 41(7):560-575. PMC: 8286140. DOI: 10.1002/cac2.12158. View

17.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H . Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World J Surg Oncol. 2013; 11:284. PMC: 3874767. DOI: 10.1186/1477-7819-11-284. View

18.

Barabasi A, Gulbahce N, Loscalzo J . Network medicine: a network-based approach to human disease. Nat Rev Genet. 2010; 12(1):56-68. PMC: 3140052. DOI: 10.1038/nrg2918. View

19.

Catania J, Fairweather D . DNA methylation and cellular ageing. Mutat Res. 1991; 256(2-6):283-93. DOI: 10.1016/0921-8734(91)90019-8. View

20.

Hua S, Quan Y, Zhan M, Liao H, Li Y, Lu L . miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting . Cancer Cell Int. 2019; 19:203. PMC: 6668076. DOI: 10.1186/s12935-019-0919-6. View